Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Thomas Fleisher"'
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Translation on this Article from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8503f7c52a990afce6ce287288e5ed31
https://doi.org/10.1158/1078-0432.22440441.v1
https://doi.org/10.1158/1078-0432.22440441.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Purpose: We report an increased incidence of EBV-induced B-cell lymphoproliferative disease (LPD) in patients treated with siplizumab, an anti-CD2 antibody. The development of EBV-LPD has been associated with the use of immunosuppressive agents used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac91bb7565e1e40c0a53634257bdd81
https://doi.org/10.1158/1078-0432.c.6517770.v1
https://doi.org/10.1158/1078-0432.c.6517770.v1
Autor:
John E. Janik, Thomas A. Waldmann, Luz Hammershaimb, Karen Kaucic, Dirk Reitsma, Paul S. Albert, Mark Raffeld, Stefania Pittaluga, Thomas Fleisher, Margaret R. Brown, Helen Matthews, Maryalice Stetler-Stevenson, John C. Morris, Deirdre O'Mahony
Supplementary Tables S1-S3 from EBV-Related Lymphoproliferative Disease Complicating Therapy with the Anti-CD2 Monoclonal Antibody, Siplizumab, in Patients with T-Cell Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df4eabde20104a650691e9673ca704c1
https://doi.org/10.1158/1078-0432.22440444.v1
https://doi.org/10.1158/1078-0432.22440444.v1
Autor:
Hyesun Kuehn, Inga Sakovich, Julie Nemela, Agustin Gil Silva, Jennifer Stoddard, Ekaterina Polyakova, Ana Esteve-Sole, Svetlana Aleshkevich, Jolan Walter, Luigi Notarangelo, Thomas Fleisher, Xiao Peng, Ottavia Delmonte, Svetlana Sharapova, Sergio Rosenzweig
Publikováno v:
Clinical Immunology. 250:109351
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::551ce932c8d456872347068e93dde9ce
https://doi.org/10.1016/j.clim.2023.109351
https://doi.org/10.1016/j.clim.2023.109351
Publikováno v:
Immunologic Research. 44:1-3
In the 1950s, Robert A. Good and his team made a series of seminal discoveries that helped to identify the distinct—yet essential—role that the thymus and equivalents of the bursa of Fabricius in chicken have for development of cell-mediated and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a06ddb0e1769ace942bc52c2a42514df
https://doi.org/10.1007/s12026-009-8110-0
https://doi.org/10.1007/s12026-009-8110-0
Publikováno v:
Journal of Autoimmunity. 10:387-394
A 52 kDa islet protein has recently been identified as the target of autoantibodies in the NOD mouse model of IDDM and humans with IDDM. However, the presence of T cell immunity against the 52 kDa islet protein in IDDM has not been reported. We repor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efc78d29bcfe085181198fa6972f5087
https://doi.org/10.1006/jaut.1997.0151
https://doi.org/10.1006/jaut.1997.0151
Autor:
Lita A Freeman, Andreas G Moraitis, Robert Shamburek, Wyndham Wilson, Cliona M Grant, Koneti Rao, Susan Price, Ronald L Hornung, Thomas Fleisher, Frank Pucino, Gabor G Illei, Alan T Remaley
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology. 33
Introduction “Disappearing HDL Syndrome” refers to cases of acquired severe HDL deficiency in non-critically ill patients. Except for rare idiosyncratic drug reactions, the physiological basis of Disappearing HDL Syndrome is not understood. Hypot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::080ca398649701ed9ca8c0790949b622
https://doi.org/10.1161/atvb.33.suppl_1.a64
https://doi.org/10.1161/atvb.33.suppl_1.a64
Autor:
Lianghao Lu, Julie Niemela, Thomas Fleisher, Joie Davis, Iusta Caminha, Mark Natter, Laurel Beer, Kennichi Dowdell, Stefania Pittaluga, Mark Raffeld, Koneti Rao, João Bosco Oliveira
Publikováno v:
The Journal of Immunology. 186:47.4-47.4
Autoimmune lymphoproliferative syndrome (ALPS) is a non-malignant disease characterized by early-onset chronic lymphadenopathy, splenomegaly, multilineage cytopenias, polyclonal hypergammaglobulinemia, expansion of circulating TCRαβ+B220+CD4-CD8- T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c376632caabbc196e7a4467913e74fa
https://doi.org/10.4049/jimmunol.186.supp.47.4
https://doi.org/10.4049/jimmunol.186.supp.47.4
Autor:
V. Koneti Rao, Jorge A. Carrasquillo, Janet K. Dale, Stephen L. Bacharach, Millie Whatley, Faith Dugan, Jean Tretler, Thomas Fleisher, Jennifer M. Puck, Wyndham Wilson, Elaine S. Jaffe, Nilo Avila, Clara C. Chen, Stephen E. Straus
Publikováno v:
American Journal of Hematology; Feb2006, Vol. 81 Issue 2, p81-85, 5p